Inhibition of inflammatory cytokine production from rheumatoid synovial fibroblasts by a novel IkappaB kinase inhibitor.
Nuclear factor-kappaB (NF-kappaB) is involved in the pathophysiology of rheumatoid arthritis (RA) and is considered to be a feasible molecular target in treating patients. In the RA joint tissues, activation of NF-kappaB is often observed together with high amounts of the proinflammatory cytokines tumor necrosis factor (TNF)alpha and interleukin (IL)-1beta. TNFalpha and IL-1beta are known to stimulate NF-kappaB signaling and are produced as the effect of NF-kappaB signaling, thus forming a vicious cycle leading to a self-perpetuating nature of rheumatoid inflammation and expansion of such inflammatory response to other joints. Because a kinase called IkappaB kinase complex (IKK) is involved in the NF-kappaB activation cascade, we examined the effect of a novel IKK inhibitor, (7-[2-(cyclopropyl-methoxy)-6-hydroxyphenyl]-5-[(3S)-3-piperidinyl]-1,4-dihydro-2H-pyrido[2,3-d][1,3]oxazin-2-one hydrochloride; CHPD), on the production of inflammatory cytokines from rheumatoid synovial fibroblasts (RSF). TNFalpha stimulation induced production of inflammatory cytokines such as IL-6 and IL-8 in RSF, and the extent of IL-6 and IL-8 induction was dramatically reduced by CHPD under noncytotoxic concentrations. Likewise, expression of il-6 and il-8 genes was significantly reduced by CHPD. In addition, chromatin immunoprecipitation assays revealed that the DNA binding of NF-kappaB (p65) to il-8 promoter in RSF was induced after TNFalpha stimulation and that, upon CHPD treatment to RSF for 1 h, the NF-kappaB binding to il-8 promoter was significantly decreased. Here, we have demonstrated that an IKKbeta inhibitor, CHPD, acts as an effective inhibitor for the production of inflammatory cytokines in response to proinflammatory cytokines. These findings indicate that such a IKKbeta inhibitor could be a feasible candidate for an antirheumatic drug.
Tsuchiya
Atsushi
A
Department of Molecular and Cellular Biology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan.
Imai
Kenichi
K
Asamitsu
Kaori
K
Waguri-Nagaya
Yuko
Y
Otsuka
Takanobu
T
Okamoto
Takashi
T
D000328:Adult; D001172:Arthritis, Rheumatoid / Q000473:pathology*; D002478:Cells, Cultured; D016207:Cytokines / Q000096:biosynthesis*; D005260:Female; D005347:Fibroblasts / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism; D006801:Humans; D051550:I-kappa B Kinase / Q000037:antagonists & inhibitors* / Q000378:metabolism; D015850:Interleukin-6 / Q000096:biosynthesis / Q000235:genetics; D016209:Interleukin-8 / Q000096:biosynthesis / Q000235:genetics; D008297:Male; D008875:Middle Aged; D016328:NF-kappa B / Q000502:physiology; D010078:Oxazines / Q000494:pharmacology*; D010766:Phosphorylation; D011725:Pyridines / Q000494:pharmacology*; D012333:RNA, Messenger / Q000096:biosynthesis; D015398:Signal Transduction; D013583:Synovial Membrane / Q000473:pathology*
C502972:7-(2-(cyclopropylmethoxy)-6-hydroxyphenyl)-5-(3-piperidinyl)-1,4-dihydro-2H-pyrido(2,3-d)(1,3)oxazin-2-one; D016207:Cytokines; D015850:Interleukin-6; D016209:Interleukin-8; D016328:NF-kappa B; D010078:Oxazines; D011725:Pyridines; D012333:RNA, Messenger; D051550:I-kappa B Kinase